journal
MENU ▼
Read by QxMD icon Read
search

International Journal of Clinical Oncology

journal
https://www.readbyqxmd.com/read/28647837/targeting-metabolic-reprogramming-in-kras-driven-cancers
#1
REVIEW
Kenji Kawada, Kosuke Toda, Yoshiharu Sakai
Mutations of KRAS are found in a variety of human malignancies, including in pancreatic cancer, colorectal cancer, and non-small cell lung cancer at high frequency. To date, no effective treatments that target mutant variants of KRAS have been introduced into clinical practice. In recent years, a number of studies have shown that the oncogene KRAS plays a critical role in controlling cancer metabolism by orchestrating multiple metabolic changes. One of the metabolic hallmarks of malignant tumor cells is their dependency on aerobic glycolysis, known as the Warburg effect...
June 24, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28643177/targeting-dna-repair-and-replication-stress-in-the-treatment-of-ovarian-cancer
#2
REVIEW
Junko Murai
Approximately half of high-grade serous epithelial ovarian cancers incur alterations in genes of homologous recombination (BRCA1, BRCA2, RAD51C, Fanconi anemia genes), and the rest incur alterations in other DNA repair pathways at high frequencies. Such cancer-specific gene alterations can confer selective sensitivity to DNA damaging agents such as cisplatin and carboplatin, topotecan, etoposide, doxorubicin, and gemcitabine. Originally presumed to inhibit DNA repair, PARP inhibitors that have recently been approved by the FDA for the treatment of advanced ovarian cancer also act as DNA damaging agents by inducing PARP-DNA complexes...
June 22, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28624863/matched-pair-analysis-of-patients-with-advanced-hypopharyngeal-cancer-surgery-versus-concomitant-chemoradiotherapy
#3
Shigemichi Iwae, Masato Fujii, Ryuichi Hayashi, Yasuhisa Hasegawa, Takashi Fujii, Kenji Okami, Akihiro Homma, Tetsuro Onitsuka, Takakuni Kato, Takenori Ogawa, Kyoichi Terao, Nobuya Monden, Naoki Otsuki, Hiroshi Nishino, Ichiro Ota, Yasushi Fujimoto, Kazuto Matsuura, Kazuyoshi Kawabata, Hidetoshi Matsui, Koichiro Yonezawa, Ken-Ichi Nibu
BACKGROUND: The aim of this study was to compare the therapeutic outcomes of total pharyngolaryngectomy with those of concomitant chemoradiotherapy in advanced hypopharyngeal cancer. METHODS: This is a retrospective multi-institutional study. The medical records of 979 patients with hypopharyngeal cancer, who were initially treated between 2006 and 2008, were reviewed. In this study, we matched a group of total pharyngolaryngectomy patients with a second group of chemoradiotherapy patients, according to age, gender, subsite, arytenoid fixation, cartilage invasion, and N classification, and analyzed overall survival, disease-specific survival, and locoregional control rates...
June 17, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28623448/comparison-between-chemoselection-and-definitive-radiotherapy-in-patients-with-cervical-esophageal-squamous-cell-carcinoma
#4
Yusuke Nakata, Nobuhiro Hanai, Daisuke Nishikawa, Hidenori Suzuki, Yusuke Koide, Yujiro Fukuda, Motoo Nomura, Takeshi Kodaira, Takeshi Shimizu, Yasuhisa Hasegawa
BACKGROUD: Laryngeal preservation is an important consideration when treating cervical esophageal cancers (CECs) such as laryngeal cancer. The standard treatment for CEC allowing laryngeal preservation is chemoradiotherapy. However, in cases of laryngeal cancer, chemoselection has also been applied as a treatment strategy that promotes larynx preservation. This strategy involves assigning the appropriate radical treatment according to the primary tumor's response to induction chemotherapy...
June 16, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28620815/radiation-related-toxicities-and-outcomes-in-endometrial-cancer-are-obese-women-at-a-disadvantage
#5
A Smits, J McGrane, A Lopes, E Kent, R Bekkers, L Massuger, N Simpson, K Galaal
OBJECTIVE: To assess the impact of body mass index (BMI) on radiotherapy toxicities in endometrial cancer patients. METHODS: This was a retrospective cohort study of women diagnosed with endometrial cancer between January 2006 and December 2014 at the Royal Cornwall Hospital Trust. Women who received radiotherapy as part of their treatment, including external beam radiotherapy (EBRT) and/or vaginal brachytherapy were included. Radiation-related toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) guidelines...
June 15, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28616753/gemcitabine-monotherapy-in-patients-with-heavily-treated-nasopharyngeal-cancer-a-case-series
#6
Tomohiro Enokida, Shinya Uozumi, Takao Fujisawa, Yuri Ueda, Susumu Okano, Makoto Tahara
BACKGROUND: Although gemcitabine is thought to play a critical role in the treatment of nasopharyngeal cancer, no research to evaluate the efficacy and toxicity of gemcitabine monotherapy has been conducted in Japan. METHODS: We retrospectively reviewed eight nasopharyngeal carcinoma patients treated with gemcitabine monotherapy at National Cancer Center Hospital East between May 2015 and August 2016. The main eligibility criteria were (1) histopathologically proven NPC; (2) tumor recurrence or an initial M1 TNM stage diagnosis; (3) at least two other types of systemic chemotherapy prior to gemcitabine; (4) no other active malignant tumor during treatment...
June 14, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28608229/erratum-to-preplanned-safety-analysis-of-the-jfmc37-0801-trial-a-randomized-phase-iii-study-of-six-months-versus-twelve-months-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer
#7
Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko, Ken Kondo, Hideyuki Ishida, Genichi Nishimura, Kazuaki Sasaki, Takayuki Morita, Shoichi Hazama, Koutarou Maeda, Hideyuki Mishima, Hideyuki Ike, Sotaro Sadahiro, Kenichi Sugihara, Masazumi Okajima, Shigetoyo Saji, Junichi Sakamoto, Naohiro Tomita
No abstract text is available yet for this article.
June 12, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28601934/salvage-endoscopic-nasopharyngectomy-for-local-recurrent-or-residual-nasopharyngeal-carcinoma-a-10-year-experience
#8
Juan Liu, Huapeng Yu, Xicai Sun, Dehui Wang, Yurong Gu, Quan Liu, Huan Wang, Wade Han, Allison Fry
BACKGROUND: Our aim was to review the outcomes of endoscopic nasopharyngectomy performed on a large series of patients with residual or recurrent nasopharyngeal carcinomas and to identify the prognostic factors. METHODS: Ninety-one patients with residual (10) and recurrent (81) nasopharyngeal carcinomas who underwent endoscopic nasopharyngectomy were enrolled in our study. Clinical information including gender, age, medical history, symptoms, radiographic findings, tumor stage, treatment, recurrence time, postoperative pathological examination, complications, and outcomes at last follow-up visit was collected...
June 10, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28600686/a-critical-prognostic-analysis-of-neutrophil-lymphocyte-ratio-for-patients-undergoing-nephroureterectomy-due-to-upper-urinary-tract-urothelial-carcinoma
#9
Mesut Altan, Hakan Bahadır Haberal, Bülent Akdoğan, Haluk Özen
BACKGROUND: To determine preoperative serum complete blood count parameters that affects survival of patients who underwent surgery for upper urinary tract urothelial cancer (UUT-UC). METHODS: Since 1990, 150 patients underwent nephroureterectomy with bladder cuff excision for UUT-UC at Hacettepe University. Patients with a history of muscle-invasive bladder cancer, adjuvant chemotherapy or metastasis at the time of diagnosis were excluded. One hundred and thirteen patients without infective symptoms and with a full set of serum data were evaluated retrospectively...
June 9, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28597346/the-rate-of-facial-nerve-dysfunction-and-time-to-recovery-after-intraparotid-and-extraparotid-facial-nerve-exposure-and-protection-in-head-and-neck-cutaneous-tumor-surgery
#10
Yasuhiro Nakamura, Yukiko Teramoto, Yuri Asami, Taichi Imamura, Sayuri Sato, Ryota Tanaka, Hiroshi Maruyama, Yoshiyuki Nakamura, Yasuhiro Fujisawa, Manabu Fujimoto, Akifumi Yamamoto
BACKGROUND: Most patients with head and neck skin tumors present with normal facial nerve function. A common treatment strategy for these patients is facial nerve preservation surgery, although the degree to which the nerve is successfully preserved is still unclear. Data on the incidence and recovery of facial nerve dysfunction are woefully lacking in the field of dermato-oncology. METHODS: In 23 patients with normal preoperative facial nerve function, we retrospectively reviewed twenty-six head and neck surgical interventions that included facial nerve exposure and protection, focusing particularly on the differences in outcome between intraparotid and extraparotid exposure of the facial nerve branches...
June 9, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28585099/recent-advances-in-targeting-dna-repair-pathways-for-the-treatment-of-ovarian-cancer-introduction
#11
REVIEW
Hiroshi Kobayashi
No abstract text is available yet for this article.
June 5, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28551815/the-efficacy-of-surgical-treatment-of-recurrent-or-persistent-cervical-cancer-that-develops-in-a-previously-irradiated-field-a-monoinstitutional-experience
#12
Seiji Mabuchi, Yuri Matsumoto, Naoko Komura, Masaaki Sawada, Mie Tanaka, Eriko Yokoi, Katsumi Kozasa, Akihiko Yoshimura, Hiromasa Kuroda, Tadashi Kimura
BACKGROUND: There are no guidelines about the selection of recurrent cervical cancer patients for salvage surgery. METHODS: Patients who developed recurrent or persistent cervical cancer in a previously irradiated field and were subsequently treated with salvage surgery (the surgery group) or palliative care alone (the palliative group) were identified. Patient characteristics, treatment-related complications, and survival were retrospectively compared between the two groups...
May 27, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28550415/high-expression-of-grp78-bip-as-a-novel-predictor-of-favorable-outcomes-in-patients-with-advanced-thymic-carcinoma
#13
Yosuke Miura, Kyoichi Kaira, Reiko Sakurai, Hisao Imai, Yoshio Tomizawa, Noriaki Sunaga, Koichi Minato, Takeshi Hisada, Tetsunari Oyama, Masanobu Yamada
BACKGROUND: Glucose-regulated protein (GRP) 78/immunoglobulin heavy chain binding protein (BiP) is a member of the endoplasmic reticulum chaperone family, and its role in various types of human malignancies has recently been investigated. However, the clinicopathological characteristics of GRP78/BiP in advanced thymic carcinoma (ATC) remain unknown. We aimed to examine the relationship between GRP78/BiP expression and the clinical outcomes of ATC patients. METHODS: Thirty-four patients with ATC receiving combination chemotherapy at three institutions between April 1998 and April 2014 were enrolled in this study...
May 26, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28550414/dasatinib-rapidly-induces-deep-molecular-response-in-chronic-phase-chronic-myeloid-leukemia-patients-who-achieved-major-molecular-response-with-detectable-levels-of-bcr-abl1-transcripts-by-imatinib-therapy
#14
Masayuki Shiseki, Chikashi Yoshida, Naoki Takezako, Akira Ohwada, Takashi Kumagai, Kaichi Nishiwaki, Akira Horikoshi, Tetsuya Fukuda, Hina Takano, Yasuji Kouzai, Junji Tanaka, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki, Koiti Inokuchi
BACKGROUND: With the introduction of imatinib, a first-generation tyrosine kinase inhibitor (TKI) to inhibit BCR-ABL1 kinase, the outcome of chronic-phase chronic myeloid leukemia (CP-CML) has improved dramatically. However, only a small proportion of CP-CML patients subsequently achieve a deep molecular response (DMR) with imatinib. Dasatinib, a second-generation TKI, is more potent than imatinib in the inhibition of BCR-ABL1 tyrosine kinase in vitro and more effective in CP-CML patients who do not achieve an optimal response with imatinib treatment...
May 26, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28547525/neoadjuvant-chemotherapy-with-trastuzumab-docetaxel-and-carboplatin-administered-every-3%C3%A2-weeks-for-japanese-women-with-her2-positive-primary-breast-cancer-efficacy-and-safety
#15
Ikuko Sugitani, Shigeto Ueda, Takashi Sakurai, Takashi Shigekawa, Eiko Hirokawa, Hiroko Shimada, Hideki Takeuchi, Kazuo Matsuura, Misono Misumi, Nobuko Fujiuchi, Takao Takahashi, Takahiro Hasebe, Akihiko Osaki, Toshiaki Saeki
BACKGROUND: This phase II neoadjuvant study evaluated the efficacy and safety of a triweekly regimen of docetaxel and carboplatin in combination with trastuzumab (TCbH) in Japanese women with human epidermal growth factor receptor type2 (HER2)-positive primary breast cancer. METHODS: Patients with HER2-positive, stage I-III invasive breast cancer received six courses of trastuzumab (8 mg/kg loading dose, then 6 mg/kg, day 1), docetaxel (75 mg/m(2), day 1), and carboplatin (area under the curve: 6, day 1) every 3 weeks...
May 25, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28536826/a-phase-ii-study-of-5-fluorouracil-l-leucovorin-oxaliplatin-mfolfox6-in-japanese-patients-with-metastatic-or-unresectable-small-bowel-adenocarcinoma
#16
Takahiro Horimatsu, Norisuke Nakayama, Toshikazu Moriwaki, Yoshinori Hirashima, Mikio Fujita, Masako Asayama, Ichiro Moriyama, Koji Nakashima, Eishi Baba, Hiroshi Kitamura, Takao Tamura, Ayumu Hosokawa, Kenichi Yoshimura, Manabu Muto
BACKGROUND: Several studies have suggested that chemotherapy prolonged survival in patients with metastatic or recurrent small bowel adenocarcinoma (SBA); however, there is still no standard chemotherapy regimen. Here, we evaluated the efficacy and safety of a 5-fluorouracil (5-FU)/L-leucovorin (l-LV)/oxaliplatin (mFOLFOX6) protocol as a first-line therapy for patients with SBA. PATIENTS AND METHODS: This was a multicenter, single-arm, open-label phase II study...
May 23, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28526907/a-prospective-study-of-xeliri-plus-bevacizumab-as-a-first-line-therapy-in-japanese-patients-with-unresectable-or-recurrent-colorectal-cancer-kscc1101
#17
Koji Ando, Yasunori Emi, Toyokuni Suenaga, Masahiro Hamanoue, Soichiro Maekawa, Yasuo Sakamoto, Seiichiro Kai, Hironaga Satake, Takayuki Shimose, Mototsugu Shimokawa, Hiroshi Saeki, Eiji Oki, Kenji Sakai, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara
BACKGROUND: This study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent colorectal cancer (CRC). METHODS: This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated unresectable or recurrent CRC, presence of measurable lesions, ≥20 years of age, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function...
May 19, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28523533/risk-factors-for-paraaortic-lymph-node-metastasis-in-endometrial-cancer
#18
Mustafa Erkan Sari, İbrahim Yalcin, Hanifi Sahin, Mehmet Mutlu Meydanli, Tayfun Gungor
OBJECTIVE: The purpose of this study was to determine the risk factors for paraaortic lymph node (LN) metastasis in endometrial cancer (EC) patients who underwent comprehensive surgical staging. METHODS: A total of 641 women with EC (endometrioid, non-endometrioid, or mixed histology) who underwent comprehensive surgical staging including pelvic and paraaortic LN dissection between 2008 and 2016 were included in this retrospective study. Patient data were analyzed with respect to paraaortic LN involvement, and predictive factors for paraaortic LN metastasis were investigated...
May 18, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28508305/recent-advances-in-targeting-dna-repair-pathways-for-the-treatment-of-ovarian-cancer-and-their-clinical-relevance
#19
REVIEW
Katsutoshi Oda, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori-Uchino, Yutaka Osuga, Tomoyuki Fujii
Poly (ADP-ribose) polymerase (PARP) inhibitors have attracted much attention as one of the major molecular-targeted therapeutics for inhibiting DNA damage response. The PARP inhibitor, olaparib, has been clinically applied for treating certain recurrent ovarian cancer patients with BRCA1/2 mutations in Europe and the United States. It was also designated on 24 March 2017 as an orphan drug in Japan for similar clinical indications. In this review, we discuss (i) the prevalence of BRCA1/2 mutations in ovarian cancer, (ii) clinical trials of PARP inhibitors in ovarian cancer, (iii) genetic counseling for hereditary breast and ovarian cancer patients, and (iv) non-BRCA genes that may be associated with homologous recombination deficiency...
May 15, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28501947/current-status-of-superficial-pharyngeal-squamous-cell-carcinoma-in-japan
#20
Ryoko Rikitake, Mizuo Ando, Yuki Saito, Seiichi Yoshimoto, Tatsuya Yamasoba, Takahiro Higashi
BACKGROUND: To investigate the status and treatment of superficial pharyngeal squamous cell carcinoma in Japan. METHODS: We analyzed all cases diagnosed between 2011 and 2013, as recorded in the national database of hospital-based cancer registries. We extracted data on patient sex, age, tumor locations, histology, presentation routes, initial treatments, and TNM stages. Additionally, we compared the characteristics of pharyngeal carcinoma to those of esophageal cancer...
May 13, 2017: International Journal of Clinical Oncology
journal
journal
32641
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"